Dr. Mark Hancock is the leading authority on mistletoe therapy in the US today. In this episode, he joins me for a powerful conversation exploring cutting-edge approaches in integrative cancer therapy you won’t hear about in conventional settings. We break down the science behind mistletoe treatment—its mechanisms, immune effects, and clinical use across subcutaneous, IV, intratumoral, and intraperitoneal delivery—along with real-world case insights. We also dive into ferroptosis, an emerging iron-dependent cancer cell death pathway gaining attention in oncology, plus the strategic use of repurposed drugs, targeted supplements, and often-overlooked blood biomarkers that can reveal deeper insights into cancer progression and treatment response. 2:50–Dr. Hancock’s backstory: discovery of anthroposophic medicine and mistletoe 4:30–UK rotations and meeting the legendary Dr. Morris Orange and seeing mistletoe in inpatient oncology 6:12–Dr. Orange’s pioneering work: high‑dose fever‑inducing mistletoe and intratumoral injections 9:55–Mistletoe mechanism of action: lectins, dendritic cells, cytokines, NK/T/B cells, apoptosis, viscotoxins, and host‑tree complexity 14:12–Host trees and formulations: 13+ host species, varying lectin/viscotoxin profiles, and the “art” of selecting mistletoe 17:30–Clinical protocols: mixing high‑lectin and endotoxin‑rich products (e.g., Abnoba + Iscador) and weekly cycling strategies 17:50–Teaching mistletoe: Hancock’s apprenticeship program and in‑depth training for providers who want to use mistletoe 18:33–Routes of administration: SubQ as the foundation, IV as the main adjunct, with intratumoral and intraperitoneal use in select cases 23:32–Germany vs. US: advanced procedural mistletoe (e.g., pancreatic injections) and leading integrative German centers (Havelhöhe, Filderklinik, Witten/Herdecke) 30:10 Case study: stage IIIC triple‑negative breast cancer—large tumor, patient refusing chemo/radiation, opting for intratumoral mistletoe 35:05–“Cold” tumors and prostate cancer: immune deserts, checkpoint inhibitor limits, and clinical responses to mistletoe 41:47–NSAIDs, COX‑2 inhibitors: how they blunt fever/skin reactions and can negate mistletoe’s desired immune effect 47:10–Titrating mistletoe: using the “mosquito‑bite” SubQ reaction and fever pattern to adjust dose and frequency 50:08–Ferroptosis 101: iron‑driven cell death, artemisinin/artesunate, IV vitamin C, and sequencing with mistletoe for immunogenic benefit 56:45-How selective is ferroptosis towards cancer cells? Potential dark side of ferroptosis 1:01:00–Biomarkers for ferroptosis and terrain: ferritin, ESR vs. CRP, LDH, and deciding when a patient is ready for treatment 1:21:26-Dr. Hancock's top 4 favorite supplements for cancer and why 1:24:55–Theoretical metabolic risks with Metformin/Berberine. LDH as glycolysis vs. tissue‑breakdown marker, Warburg effect context. Potential for guiding use of DCA/Metformin/Berberine 1:36:12-Dr. Hancock's top 3 favorite repurposed drugs and why 1:42:11-Clinical pearls regarding ferroptosis and autophagy that NO ONE talks about 1:47:12-Dr. Hancock's 3 favorite blood biomarkers 1:54:20-Dr. Hancock’s mistletoe training via PAAM and his apprenticeship https://anthroposophicmedicine.org/mistletoe-course https://humanizingmedicine.com/ https://mistletoetherapy.com/team/mark-hancock-md-mph/
